Search

SUMARI: Salutació.Crònica reial.La host.La torre dels Alçaments (i II).Casa i Cort dels reis d'Aragó (II).El bou en la cultura mediterrània.Joan Fuster,"in memoriam".Les illes columbretes.Bernat de Ventadorn, trobador d'ofici.Sant Antoni: Animals, dimonis i foc.III Capitol de l'arros i la taronja.Decàleg de promeses solemnes.Decàleg de promeses solemnes.Guijuelo:23-II-97 I capitol del jamón (XII jornadas de la matanza).Hernani: 23-III-97 II capítol de la sidra.Santander: 20-IV-97 XIII Capítol del Queso de Cantabria.Noreña: 27-IV-97 VII capítol la orden del Sabadiego.Espelette: 3-V-97 VIII capitol de Fecoca.Calendario: 3-V-97 I capitol del gremio del chorizo. Tudela: 4-V-97 III capitol de la orden del Volatín.Donostia: 25-V-97 V capitol de la anchoa del Cantábrico.Burgos: 15-VI-97 X capitol de la morcilla burgensis.Valladolid: 9-XI-97 III capitol de los vinos y viandas de Castilla León.Bilbao: 30-XI-97 IX capitol de la confraria Europea del vino i el txacolí.Guimaraes: 22-XI-97 I capitol extraordinari de Panela ao Lume.Activitats de l'any 1997.Viatges de la gent de la host.Els Alcaids del castell vell.Gala dels Alcaids 1998.La nostra patrona.Balanç de 10 anys.L'adéu d'un amic i un pare.Pregó de la host.Els nostres 10 pregons.La foguera de la magdalena.Associacions festeres amigues: colla pasparis.Gastronomia festera: marudatge de plats amb els vins.Programa de festes magdalena '98.

We present the case report of a preterm, low weight newborn with dysmorphic features and micrognathia in whom a laryngeal mask airway was inserted and maintained for 44 h for ventilatory support after several failed intubations. No complications associated with laryngeal mask airway use were apparent.

por una ONG a un hospital espanol, con el diagnostico de elefantiasis por filarias en miembro inferior derecho, para realizarle amputacion. Procedia de una zona de Africa endemica en esa parasitosis. Desde los 18 meses de edad comenzo con engrosamiento de la pierna derecha (Fig. 1). No constaban mas antecedentes. Al ingreso destacaba un gran tamano de la extremidad que le impidia mantenerse en pie desde mas de tres anos antes. Presentaba escoliosis y deformidades toracicas atribuidas a la malposicion cronica y tambien anemia microcitica ferropenica. El peso total era de 50 kg. Se realizo la desarticulacion de la cadera con anestesia general precisando importante reposicion hematica y de fluidos. El peso de la pieza fue 20 kg. Tras dos dias de estancia en la UCI, paso a la sala de hospitalizacion sin haber presentado complicaciones. El diagnostico anatomopatologico de la pieza fue neurofibromatosis grado I. En la resonancia magnetica se detecto un nodulo cerebral. Posteriormente se le coloco una protesis antes de volver a su pais.

Traditionally, economists have been concerned over factors that improve economic growth, initially introducing physical capital and later human capital. We will consider a new factor, social capital. Also, we will introduce in this paper the effect of the fiscal policy on economic growth. In addition, we will analyse the effects that the use of fiscal policy has on economic growth. Concretely, we will study public capital, which if it introduces production factors, as well as physical capital, human capital and social capital, could influence economic growth. Finally, we will realise an econometric estimation to analyse the effects of these production factors on economic growth using data for European countries before amplification for the period 1982–2000.

Rituximab in combination with CHOP-like chemotherapy has demonstrated to improve the results in young and elderly patients with DLBCL compared to chemotherapy alone. Re-treatment with rituximab is feasible in patients with indolent lymphoma, but there is few data on the effect of rituximab in combination with chemotherapy in the re-treatment of relapsed patients with DLBCL who have respond previously to rituximab + chemotherapy. In order to investigate the effect of rituximab in this setting, we have performed a multicenter retrospective study in 50 patients with DLBCL re-treated with rituximab in combination with chemotherapy. We have included in this study 46 patients (31 males, 15 females), median age 60 (range, 20 to 81 years), who achieved CR with the previous rituximab-containing regimen. At initial diagnosis, 32 patients had Ann-Arbor stage III or IV and 20 patients had IPI 3 or 4. The median interval between courses was 14.7 months. The most frequent regimens administered as up-front therapy in combination with rituximab were CHOP-like regimens (30 patients) and the commonest chemotherapy regimens used as salvage therapy were R-ESHAP (20 patients), R-ICE (7 patients), rituximab in combination with gemcitabine-based regimens (4 patients) and TTR (3 patients). The overall response rate in the assessable population was 81% (46% CR, 35% PR). In 25 assessable patients who have received rituximab in combination with chemotherapy as second-line therapy, the overall response rate was 92% (56% CR, 36% PR). The overall response rate was slightly lower in those patients re-treated with rituximab as third-line therapy (78% with 33% CR and 45% PR). The follow-up is too shorter (median 6 months) to assess the impact of re-treatment on duration of remission. The adverse events were not different to those usually observed with these regimens. In conclusion, the re-treatment with rituximab in relapsed patients with DLBCL who had respond previously to rituximab in combination with chemotherapy seems not to compromise the results in terms of response. Logically, larger prospective studies are necessary to confirm these encouraging results.

We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules., The authors received editorial/writing support provided by Christian Geest, PhD, from Excerpta Medica, funded by Celgene Corporation. The authors had full access to the data and are fully responsible for content and editorial decisions for this manuscript.